JP2006511520A - プラバスタチンおよびアスピリン含有多層錠および方法 - Google Patents

プラバスタチンおよびアスピリン含有多層錠および方法 Download PDF

Info

Publication number
JP2006511520A
JP2006511520A JP2004559355A JP2004559355A JP2006511520A JP 2006511520 A JP2006511520 A JP 2006511520A JP 2004559355 A JP2004559355 A JP 2004559355A JP 2004559355 A JP2004559355 A JP 2004559355A JP 2006511520 A JP2006511520 A JP 2006511520A
Authority
JP
Japan
Prior art keywords
aspirin
pharmaceutical composition
layer
pravastatin
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004559355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511520A5 (enExample
Inventor
ルートフィ・バンケルール
オリヴィエ・ガレー
フランソワーズ・キネ
アドマス・アベベ
ピーター・ティミンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006511520(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2006511520A publication Critical patent/JP2006511520A/ja
Publication of JP2006511520A5 publication Critical patent/JP2006511520A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004559355A 2002-12-11 2003-12-03 プラバスタチンおよびアスピリン含有多層錠および方法 Pending JP2006511520A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method
PCT/US2003/038774 WO2004052289A2 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Publications (2)

Publication Number Publication Date
JP2006511520A true JP2006511520A (ja) 2006-04-06
JP2006511520A5 JP2006511520A5 (enExample) 2006-12-14

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004559355A Pending JP2006511520A (ja) 2002-12-11 2003-12-03 プラバスタチンおよびアスピリン含有多層錠および方法

Country Status (17)

Country Link
US (1) US20040115265A1 (enExample)
EP (1) EP1581194B1 (enExample)
JP (1) JP2006511520A (enExample)
AT (1) ATE401061T1 (enExample)
AU (1) AU2003297689A1 (enExample)
CY (1) CY1108414T1 (enExample)
DE (1) DE60322264D1 (enExample)
DK (1) DK1581194T3 (enExample)
ES (1) ES2308040T3 (enExample)
IS (1) IS2877B (enExample)
MY (1) MY140947A (enExample)
NO (1) NO338696B1 (enExample)
PL (1) PL206190B1 (enExample)
PT (1) PT1581194E (enExample)
SI (1) SI1581194T1 (enExample)
TW (1) TWI361700B (enExample)
WO (1) WO2004052289A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509367A (ja) * 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 積層製剤
JP2020094025A (ja) * 2018-12-11 2020-06-18 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
WO2007027566A2 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
KR101330096B1 (ko) * 2007-10-12 2013-11-15 페링 인터내셔널 센터 에스 에이 구연산, 산화 마그네슘, 중탄산칼륨 및 피코황산나트륨을 포함하는 의약품의 제조 방법, 이러한 방법에 의해 제조된 과립을 포함하는 약제학적 조성물 및 중간체
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
JP5905031B2 (ja) * 2011-01-28 2016-04-20 インタッチ テクノロジーズ インコーポレイテッド モバイルテレプレゼンスロボットとのインタフェーシング
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05294829A (ja) * 1992-02-17 1993-11-09 Lion Corp イブプロフェン含有製剤
JP2002506809A (ja) * 1998-03-18 2002-03-05 ブリストル−マイヤーズ スクイブ カンパニー スタチンおよびアスピリン含有医薬組成物
JP2005504064A (ja) * 2001-08-28 2005-02-10 ロングウッド ファーマシューティカル リサーチ， インコーポレイテッド コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05294829A (ja) * 1992-02-17 1993-11-09 Lion Corp イブプロフェン含有製剤
JP2002506809A (ja) * 1998-03-18 2002-03-05 ブリストル−マイヤーズ スクイブ カンパニー スタチンおよびアスピリン含有医薬組成物
JP2005504064A (ja) * 2001-08-28 2005-02-10 ロングウッド ファーマシューティカル リサーチ， インコーポレイテッド コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509367A (ja) * 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 積層製剤
KR101479324B1 (ko) * 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20150046390A (ko) * 2006-11-09 2015-04-29 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR101654176B1 (ko) * 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20170002660A (ko) * 2006-11-09 2017-01-06 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR101735466B1 (ko) * 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR101971218B1 (ko) * 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
JP2020094025A (ja) * 2018-12-11 2020-06-18 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法
JP7109748B2 (ja) 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Also Published As

Publication number Publication date
EP1581194B1 (en) 2008-07-16
TW200505432A (en) 2005-02-16
CY1108414T1 (el) 2014-02-12
WO2004052289A3 (en) 2005-03-24
IS7889A (is) 2005-06-10
NO20052734D0 (no) 2005-06-07
DE60322264D1 (de) 2008-08-28
US20040115265A1 (en) 2004-06-17
PL377265A1 (pl) 2006-01-23
ES2308040T3 (es) 2008-12-01
NO338696B1 (no) 2016-10-03
TWI361700B (en) 2012-04-11
AU2003297689A8 (en) 2004-06-30
AU2003297689A1 (en) 2004-06-30
EP1581194A4 (en) 2006-03-15
ATE401061T1 (de) 2008-08-15
PL206190B1 (pl) 2010-07-30
DK1581194T3 (da) 2008-10-20
EP1581194A2 (en) 2005-10-05
WO2004052289A2 (en) 2004-06-24
SI1581194T1 (sl) 2008-12-31
NO20052734L (no) 2005-07-07
MY140947A (en) 2010-02-12
PT1581194E (pt) 2008-09-24
IS2877B (is) 2014-04-15

Similar Documents

Publication Publication Date Title
EP1581194B1 (en) Multilayered tablet containing pravastatin and aspirin and method
AU760520B2 (en) Pharmaceutical composition containing a statin and aspirin
KR101207618B1 (ko) 심혈관계 질환 치료용 약제학적 제제
KR101298788B1 (ko) 안정성이 개선된 복합제제
US7915247B1 (en) Methods of use of fenofibric acid
US20110008426A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
TW201442742A (zh) 祛鐵斯若（ｄｅｆｅｒａｓｉｒｏｘ）之口服配方
EP2255796A2 (en) Pharmaceutical preparation
AU2008288106A1 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
US20110052683A1 (en) Pharmaceutical preparation for treating cardiovascular disease
CN101594850A (zh) 降血脂药物组合物和及其制备方法
US20090196935A1 (en) Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
WO2005011642A9 (en) Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
CA2571447A1 (en) Composition and method for treatment and prevention of atherosclerosis
KR101072600B1 (ko) 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법
US20070160663A1 (en) Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
MXPA00008429A (en) Pharmaceutical composition containing a statin and aspirin
JP2009256237A (ja) 固形製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810